Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

Summary

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate works after stereotactic radiosurgery in treating patients with newly diagnosed brain metastases.

Timeline

Start

2009-04

Primary completion

2012-01

Completion

2014-04

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Drugs

Indications